Spinal cord injury drug moves into next phase of trials

16 September 2010
After successfully improving muscle tone in spinal cord injury patients in clinical trials, a new drug is progressing into the next phase of tests.

Arbaclofen placarbil (AP), also known as XP19986, will be tested on multiple sclerosis (MS) patients in Phase 3 clinical trials, the drug's maker biopharmaceutical firm Xenoport has said.